Rocket Lab USA RKLB
Industrials · Aerospace & Defense · Synthos Deep Dive · 2026-07-03
The Overview
Rocket Lab builds and launches rockets and satellites. Its small "Electron" rocket already flies to space regularly, it builds satellites and spacecraft parts for other companies and governments, and it is building a bigger rocket called Neutron to compete for the heavier launches that today mostly go to SpaceX.
The business is growing fast (sales up 38% last year, up 63% in the latest quarter) but it still loses money — it has not turned a profit yet. And the stock is very expensive: you are paying about 84 dollars for every 1 dollar of yearly sales, which only makes sense if the company grows into that price over many years. Our verdict is Buy but keep it small — this is a swing-for-the-fences holding, not a safe anchor.
Here is what our three scores mean in everyday terms:
- Downside Risk 8/10 (high). The company has plenty of cash and little debt, which is good — but the stock is priced for perfection, swings about 2.5× as hard as the market, and has already fallen a third from its high. A stumble could hurt a lot.
- Growth Quality 7/10 (good, not proven). Sales are growing fast and the profit margin on each sale is improving, but the company still isn't profitable overall.
- Exponential Potential 8/10 (high). It is still small and speeding up, chasing an enormous market — the kind of setup that can multiply, if it executes.
The one big worry: the new Neutron rocket. Much of today's price assumes Neutron works and wins business. If it is badly delayed or fails, the stock has a long way to fall.
Putting a number on it: our fair-value estimate is $92 against a current price of $64.39 — real upside if our numbers are right.
Our summary metrics
Net-cash balance sheet, but 84× EV/sales, beta 2.5, still loss-making, and a −33% drawdown already show the volatility.
~35% forward revenue CAGR and rising gross margin, but no profit yet and returns on capital are negative.
Small ($58B) name accelerating into a huge launch/space-systems TAM with Neutron optionality — a genuine exponential candidate.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, We don’t publish a reverse-DCF cross-check for pre-profit companies — negative or missing earnings break that math — so take this number on our modeling alone.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Small ($58B) name accelerating into a huge launch/space-systems TAM with Neutron optionality — a genuine exponential candidate.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $111.22 (high $135 / median $120 / low $69; 14 Buy · 4 Hold · 1 Sell) — context, not our anchor |
| Valuation | Not meaningful on earnings (loss-making) · EV/sales 84× TTM · ~22× FY30E sales · P/E ~109× FY30E |
| Technicals | Pulled back — $100, −33% off the 52-wk high, below the 50-DMA, above the 200-DMA, RSI 41, but +193% 12-mo (SPY +21%) |
| Conviction | Low-Moderate — only 3 net-bullish voices / 4 claims, high-skill but thin; one explicitly trimming on key-man risk |
| Position sizing | Satellite / high-beta sleeve, ~1–2.5% — not a core holding |
What the experts actually said 7 traceable claims on RKLB · showing the highest-conviction voices
“Falling credit spreads push capital to the frontier; Rocket Lab is a favored frontier/space play (trades like crypto).”
“Rocket Lab back at all-time highs and counting to a weekly eight; excellent long setup, traded twice well.”
“High-conviction winner worth holding but actively trimming to manage single-stock/key-man (Neutron, Peter Beck) risk.”
“Rapid reusability is the rate-limiting breakthrough; sure Rocket Lab's Neutron will get to reusable first and second stage, alongside Starship and New Glenn, bringing launch costs down.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $64.39, 17% below the 50-day average ($78), 19% below the 200-day average ($79) — a downtrend. 57% below the 52-week high of $150, 63% above the 52-week low of $39.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $64.39 is currently inside the band (band $63–$86).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 35.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.96, negative momentum.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = RKLB · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Rocket Lab USA (NASDAQ: RKLB), founded 2006, headquartered in Long Beach, California, led by founder-CEO Sir Peter Beck, is a vertically-integrated space company. It does two things:
- Launch Services — the Electron small orbital rocket (the second-most-launched US rocket after SpaceX's Falcon 9) plus HASTE suborbital variants, and the in-development Neutron, a reusable medium-lift rocket (~8-ton payload class) aimed squarely at the constellation/defense market SpaceX dominates.
- Space Systems — satellites, spacecraft (the Photon platform), star trackers, reaction wheels, solar arrays, separation systems and other components sold to commercial, prime-contractor and government customers; this now includes full constellation-management and on-orbit services.
Fiscal year ends December 31. 2,100 full-time employees.
Revenue mix (FY2024, latest FMP segmentation):
- By product: Space Systems $310.8M (71%) · Launch Services $125.4M (29%). The systems arm — not launch — is the larger and faster-growing engine today; this is a satellite-manufacturing company that also flies rockets.
- By geography (FY2024): United States $268.3M (62%) · Canada $104.4M · Rest of World $32.8M · Japan $30.7M. US-concentrated and increasingly defense-linked.
2. The expert thesis — why the panel leans bullish (traceable)
Coverage in the Synthos KB is thin: only 4 traceable claims from 3 net-bullish voices plus effectively one cautionary lens. This is a materially lower-breadth name than a flagship compounder — the verdict is therefore more quant- and fundamentals-driven than conviction-driven, and we say so plainly. What coverage exists is high-skill (all skill 1.0):
- Frontier / macro-liquidity bull. Forward Guidance (
forward_guidance-Bufb-D6P7Ok:98b86088d2, bullish, conviction 75, 2025-06-27): falling credit spreads push capital to the frontier, and "Rocket Lab is a favored frontier/space play (trades like crypto)." An honest read of what this is — a high-beta, liquidity-sensitive risk asset, not a value stock. - Momentum / technical bull. Raoul Pal (
raoul_pal_m-k0ljkkVWaqA:3b776fa0f9, bullish, conviction 65, 2025-06-12): Rocket Lab "looks excellent, back at all-time highs; a well-traded add though it may pause on a weekly-eight count." A trading endorsement with an explicit near-term-pause caveat. - High-conviction owner — who is trimming. Invest Like the Best (
invest_like_the_best-gAofwjnSWJE:16458f0bea, bullish, conviction 55, 2026-03-08): a "high-conviction winner worth holding but actively trimming to manage single-stock / key-man (Neutron, Peter Beck) risk." This is the most recent claim and the most useful: even the bull is sizing down, naming Neutron execution and founder key-man risk as the reasons.
Honest composite note. The signed panel is net-bullish (net conviction ~+65), but it is thin, it is dominated by macro/momentum framing rather than deep fundamental underwriting, and the single most recent voice is trimming. That combination is exactly why this is a Satellite, not a Core — and why the quant/fundamental case below does the heavy lifting.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 8 · High | Net-cash balance sheet (~$575M net cash) is a genuine cushion, but 84× EV/sales, beta 2.5, still-negative EBITDA/FCF, an FMP letter rating of C-, and an already-realized −33% drawdown all say this trades like an option. |
| Growth Quality | 7 · Good (unproven) | ~35% forward revenue CAGR, gross margin rising to 36.6% TTM (from ~24% two years ago), diversified across launch + systems + defense — but returns on capital are still negative and profitability is years out. |
| Exponential Potential | 8 · High | A small ($58B) name whose growth is accelerating (+63% YoY in Q1'26) into a launch + space-systems TAM in the hundreds of billions, with Neutron as call-option upside. This is what a real exponential candidate looks like. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–24-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Because RKLB is loss-making near-term, we anchor on an EV/sales exit multiple applied to a forward revenue estimate, sanity-checked against FY30E EPS.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Neutron reaches orbit on schedule and wins recurring defense/constellation launch; Space Systems keeps compounding >30%. FY30E revenue beats to ~$3.0B; the market keeps paying a scarcity premium ~10× EV/sales on that year. | ~$165 (+64%) |
| Base (our anchor) | Estimates roughly hit — FY30E revenue ~$2.66B (Street avg), Neutron ramps but slower than hoped; multiple compresses toward ~7.5× EV/sales as the story de-risks into profitability (FY30E EPS ~$0.92). Discounted back, that is a fair value modestly below today's price. | ~$92 (−8%) |
| Bear | Neutron slips multiple years or fails a flight; systems growth decelerates; risk appetite for unprofitable frontier names contracts. Revenue path halves vs base and the multiple de-rates to ~4× EV/sales. | ~$38 (−62%) |
Synthos fair value = the base case, ~$92 (−8%), with the full $38–$165 span as the honest range. Note the range is highly asymmetric and wide — a hallmark of an early, option-like name. Our base sits below the Street's $111 consensus because we are less willing to pay today for a Neutron ramp that has not yet flown; our bull roughly reaches the Street high, and our bear takes an execution failure seriously in a way sell-side targets rarely do. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). RKLB is a genuine exponential candidate — small, accelerating, huge runway — with the profitability question still open:
- Forward growth: revenue CAGR FY25→FY30E ~34.6% ($601.8M → $2.66B Street avg). EPS crosses from −$0.37 (FY25) to roughly breakeven (FY27E) to +$0.92 (FY30E) — an inflection, not just a ramp.
- Acceleration (the 2nd derivative) is positive: revenue growth was +38% (FY25) and Q1'26 printed +63% YoY ($200.3M vs $122.6M). Unlike a decelerating mega-cap, RKLB's growth is speeding up as Space Systems scales and Neutron approaches. That positive second derivative is the single best argument for the name.
- Room to run: at $58B market cap against a global launch + satellite-manufacturing + on-orbit-services TAM measured in the hundreds of billions (and growing with defense/constellation demand), the law of large numbers is not yet the binding constraint. Execution is.
- Reinvestment runway: heavy, deliberate capex (FY25 capex −$156M, plus $132M of acquisitions) funded by a $1.25B equity raise — building the Neutron pad, engine test infrastructure and systems capacity. Reinvestment is aggressive and, so far, productive on the top line.
Exponential Potential: High (8/10). This is exactly the forward next-exponential profile — small, accelerating, enormous TAM, real optionality (Neutron) — that belongs in the Satellite sleeve. The score is high on potential; it is not a statement that the outcome is safe (see Downside Risk 8).
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $601.8M, +38.0% (FY24 $436.2M, +78% on FY23 $244.6M). Multi-year acceleration.
- Quarterly trajectory (real acceleration): Q1'25 $122.6M → Q2 $144.5M → Q3 $155.1M → Q4 $179.7M → Q1'26 $200.3M (+63.4% YoY). Sequential and YoY momentum both intact.
- Margins: gross 36.6% TTM (34.4% FY25, up from ~21% in FY23) — real operating leverage in cost of revenue. But operating margin is −33% TTM, EBITDA margin −22% TTM: heavy R&D (43.6% of revenue TTM — the Neutron/engine spend) and SG&A keep the company deeply unprofitable.
- Earnings: net loss −$198.2M FY25 (EPS −$0.37), roughly flat vs FY24's −$190.2M as revenue growth is reinvested. Q1'26 net loss −$45.0M (narrowing as a % of revenue).
- Cash flow: operating CF −$165.5M and FCF −$321.8M FY25 (capex −$156M) — the buildout burns cash. This is the key watch-item: the story requires the burn to inflect as Neutron revenue arrives.
- Balance sheet (the cushion): cash + short-term investments $1.02B, total debt $254M, net cash ~$575M (net debt −$574.7M). Current ratio 4.5×. The FY25 $1.25B equity raise funds the runway — but note it also diluted shareholders (weighted shares rose from ~496M to ~605M by Q1'26), a structural cost of financing an unprofitable growth story.
6. Valuation — priced in or room?
There is no honest way to call RKLB cheap. On trailing numbers it is 84× EV/sales and 86× price/sales, with no P/E (loss-making) and an FMP quantitative letter rating of C- (overall score 1/5). The bull's entire defense is forward: on the Street's FY30E revenue of $2.66B, today's ~$58B EV is ~22× FY30E sales, and FY30E EPS of $0.92 is a ~109× forward P/E — still rich five years out. Put differently, the reverse-DCF read is that the market is already pricing a substantially larger, profitable Rocket Lab — i.e. that Neutron works and Space Systems keeps compounding. There is essentially no margin of safety in the multiple; the margin of safety is the balance sheet, not the price. Street targets (context): consensus $111.22, median $120, high $135, low $69. Our $92 base FV is below consensus precisely because we discount an un-flown Neutron. A momentum/optionality buy at a full price — never a value buy.
7. Technicals (from the FMP tech block)
- Trend: mixed / cooling. $100.46 sits below the 50-DMA ($106.93) but well above the 200-DMA ($75.88) — the intermediate trend has rolled over while the long-term uptrend holds. MACD −4.49 (negative).
- Location: −33.1% off the 52-week high ($150.23) and +181.7% off the 52-week low ($35.66) — a violent range. The −33% max drawdown from peak is the volatility this name carries, made concrete.
- Momentum: RSI(14) 40.8 — neutral-to-weak, not oversold, no bounce signal, no overbought warning.
- Relative strength (the tell): RKLB +192.6% 12-mo vs SPY +20.6% and QQQ +30.3%; +53.3% 3-mo vs SPY +13.7%. Enormous outperformance over a year, but the 3-month has cooled and it is now under its 50-DMA.
- Read: technicals say a leadership name in a mid-cycle pullback — up huge over a year, down a third from the high, currently below the 50-DMA with weak momentum. Not a technically clean entry; a base above the rising 200-DMA (~$76) or a reclaim of the 50-DMA would be lower-risk add points. This matches the fundamental view: attractive story, wait for a better price / more Neutron evidence.
8. Moat & competitive position
Rocket Lab's edge is vertical integration + scarcity: it is one of very few companies (SpaceX being the dominant other) that both operates an orbital rocket and manufactures satellites and spacecraft components end-to-end. Electron is the established #2 US launcher by cadence; the Space Systems arm gives a second, less binary revenue engine and pulls Rocket Lab up the value chain toward owning constellations and on-orbit services. The moat is real but narrow and contested: SpaceX's scale and cost advantage is structural, and Neutron enters a medium-lift market SpaceX already dominates. The durability of the moat is therefore entirely tied to Neutron's execution and to continued Space Systems wins.
Peer set (FMP-tagged, market cap): EMCOR $34.5B, Elbit Systems $37.6B, Comfort Systems $61.3B, HEICO $50.4B, Otis $28.1B, United Airlines $43.3B, Verisk $24.7B, Wabtec $44.5B, Xylem $28.1B. Note these are FMP's Industrials comps (defense/A&D and industrial services), not pure-play space — the only true public comparable (SpaceX) is private, which is itself part of the scarcity thesis. RKLB commands a far higher sales multiple than any listed peer, reflecting growth and scarcity, not current fundamentals.
9. Management, capital allocation & guidance
- Founder-led: Sir Peter Beck founded Rocket Lab in 2006 and remains CEO — a genuine visionary operator, but also the key-man risk the KB explicitly flags (
invest_like_the_best-gAofwjnSWJE:16458f0bea). - Capital allocation: aggressive forward reinvestment — FY25 capex −$156M and $132M of acquisitions (building intangibles/goodwill from $130M to $430M), funded by a $1.25B equity raise. Appropriate for a land-grab phase, but it means dilution is the funding model until FCF turns; watch share count.
- Insider activity: a mix in the sampled window — SVP/GC Kampani sold 88,000 shares at $107.98 (2026-06-18) and a director sold 40,000 at $123.60 (2026-06-02), alongside routine equity awards to the CFO and controller. Some open-market selling near the highs, but no alarming discretionary cluster; largely normal for a post-run-up equity-comp-heavy company.
- Guidance: management guides revenue and gross-margin ranges by quarter and Neutron milestone timing on the earnings call. Treat management's Neutron-timeline commentary as a book-talking voice — the schedule has moved before, as it does across the whole launch industry.
10. Catalysts & what to watch
- Next earnings: 2026-08-06 (Q2'26; Street EPS −$0.05, revenue ~$232M). Watch Space Systems growth, gross-margin trajectory, and cash burn.
- Neutron first flight / test milestones: the single biggest swing factor — engine hot-fires, stage tests, pad readiness, and ultimately an orbital attempt. Any slip is a de-rating catalyst; success is the bull case.
- Launch cadence (Electron/HASTE): quarterly launch count is the clearest volume tell.
- Defense / government awards: recurring national-security launch and systems contracts would harden the revenue base.
- Cash-burn inflection: the moment operating cash flow starts trending toward breakeven confirms the model; continued deep burn + another raise is the bear tell.
Thesis tripwires (what would change the call): a multi-year Neutron delay or flight failure; Space Systems growth decelerating below ~20%; gross margin stalling; or a second large dilutive raise without a revenue step-up.
11. Key risks
- Neutron execution (structural, #1): the premium valuation assumes a rocket that has not yet flown. Delay or failure is the dominant risk — and even the KB bull is trimming for it (
invest_like_the_best-gAofwjnSWJE:16458f0bea). - Valuation / de-rating: 84× sales and no profits leave zero margin for disappointment; RKLB "trades like crypto" per its own bull (
forward_guidance-Bufb-D6P7Ok:98b86088d2) — i.e. it is a liquidity-sensitive, high-beta (2.5) risk asset. - Profitability is years away: −$322M FCF and negative returns on capital; the path to profit depends on scale that is not yet in the numbers.
- Dilution: an unprofitable growth model funded by equity raises — share count has already risen ~20% in a year.
- Competitive / key-man: SpaceX's structural cost lead in medium-lift, plus dependence on founder Peter Beck (
invest_like_the_best-gAofwjnSWJE:16458f0bea). - Cyclicality of risk appetite: as a "frontier" asset, RKLB is highly exposed to macro-liquidity and credit-spread swings (
forward_guidance-Bufb-D6P7Ok:98b86088d2) — it can fall hard in a risk-off regime regardless of company execution.
12. Verdict, position sizing & monitoring
Buy — Tactical. Rocket Lab is a genuine forward next-exponential: small ($58B), accelerating (+63% YoY revenue in Q1'26), rising gross margins, a net-cash balance sheet, and a scarcity position as the only listed vertically-integrated space company besides SpaceX. That is a real, ownable growth story. But it is still loss-making, priced at 84× sales, carries a 2.5 beta, has already drawn down 33%, and the KB coverage is thin and led by a bull who is trimming — so this is emphatically a small, high-volatility satellite position, not a core anchor. Our base-case fair value ($92) sits slightly below both the current price and the Street's $111, reflecting an un-flown Neutron; the upside case ($165) is real but option-like.
- Sizing: satellite / high-beta sleeve, ~1–2.5%. Because the range is so wide, scale in on weakness and on Neutron de-risking rather than chasing; a base above the 200-DMA (~$76) or a 50-DMA reclaim are better entries than current levels.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print and on every major Neutron milestone. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $100.46.
- Single biggest risk: Neutron — if the medium-lift rocket slips for years or fails, the premium valuation unwinds hard.
Provenance & disclosures
- Traceability: 4 KB claims, breadth 3 net-bullish voices (+1 cautionary lens), top skill 1.0, last claim 2026-03-08 — all reconciled to real
claim_ids (cited inline). Coverage is thin; the verdict is explicitly more quant/fundamentals-driven than conviction-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation). - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · expert claims through 2026-03-08. Forward figures are analyst consensus (FMP), labeled as estimates. Note: FMP's FY27–FY30 EBITDA estimate lines are internally inconsistent (deeply negative alongside positive net income); we relied on the revenue, net-income and EPS estimate lines and flag the EBITDA lines as unreliable.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").